Minjuvi (tafasitamab)

pCPA File Number: 22052

Negotiation Status:

Concluded with an LOI

Indication(s):

in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant

Sponsor/Manufacturer:

Incyte Biosciences Canada Corporation

CADTH Project Number:

PC0266

pCPA Engagement Letter Issued:

2023-05-26

Negotiation Process Concluded:

2023-08-08